Hsp90 inhibitor Geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin

Neoplasma

Volumn 54, Issue 2, 2007, Pages 127-130

  Solar P ^a   Horvath V ^b   Kleban, J ^c   Koval', J ^c   Solarova Z ^a   Kozubik A ^b   Fedorocko P ^c  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b INSTITUTE OF MATHEMATICS   (Czech Republic)

^c NONE

Author keywords

A2780cis; Chemoresistance; Cisplatin; Geldanamycin; Hsp90

Indexed keywords

CISPLATIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; ENZYME INHIBITOR; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CAUSE OF DEATH; CELL CYCLE S PHASE; CELL STRAIN A27CIS; CONTROLLED STUDY; CYTOTOXICITY; DEPLETION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MONOTHERAPY; OVARY ADENOCARCINOMA; ADENOCARCINOMA; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG RESISTANCE; OVARY TUMOR; PATHOLOGY; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BENZOQUINONES; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 34347209096     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. ASSELIN E, MILLS GB, TSANG BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001; 61: 1862-1868.
2. HAYAKAWA J, DEPATIE C, OHMICHI M, MERCOLA D. The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. J Biol Chem 2003; 278: 20582-20592.
3. TSURUO T, NAITO M, TOMIDA A, FUJITA N, MASHIMA T, SAKAMATO H, HAGA N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003; 94: 15-21.
4. SAMIMI G, SAFAEI R, KATANO K, HOLZER AK, ROCHDI M, TOMIOKA M, GOODMAN M, HOWELL SB. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 2004; 10: 4661-4669.
5. SELVAKUMARAN M, PISARCIK DA, BAO R, YEUNG AT, HAMILTON TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003; 63: 1311-1316. (Pubitemid 36348710)
6. ROSE PG, MOSSBRUGER K, FUSCO N, SMREKAR M, EATON S, RODRIGUEZ M. Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol 2003; 88: 17-21.
7. PARKER RJ, EASTMAN A, BOSTICK-BRUTON F, REED E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991; 87: 772-777.
8. YUAN ZQ, FELDMAN RI, SUSSMAN GE, COPPOLA D, NICOSIA SV, CHENG JQ. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem 2003; 278: 23432-23440.
9. SATO S, FUJITA N, TSURUO T. Modulation of Akt kinase activity by binding to HSP90. Proc Natl Acad Sci USA 2000; 97: 10832-10837. (Pubitemid 30751239)
10. NECKERS L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002; 8: S55-S61. (Pubitemid 34297080)
11. PRATT WB, TOFT DO. Regulation of signalling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med 2003; 228: 111-133. (Pubitemid 36187918)
12. VASILEVSKAYA IA, RAKITINA TV, O'DWYER PJ. Geldanamycin and its 17-allylamino-17-demethoxygeldanamycin analogue antagonize the action of cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basic for interaction. Cancer Res 2003; 63, 3241-3246.
13. RAKITINA TV, VASILEVSKAYA IA, O'DWYER PJ. Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor κB signaling. Cancer Res 2003; 63: 8600-8605.
14. MCILWRATH AJ, BRUNTON VG, BROWN R. Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumour cells. Cancer Chemother Pharmacol 1996; 37: 423-428.
15. KOZUBIK A, HORVATH V, SVIHALKOVA-SINDLEROVA L, SOUCEK K, HOFMANOVA J, SOVA P, KROUTIL A, ZAK F, MISTR A, TURANEK J. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochem Pharmacol 2005; 69: 373-383.